InMed Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

De CEO InMed Pharmaceuticals is Eric Adams, benoemd in Jun2016, heeft een ambtstermijn van 8.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 415.40K, bestaande uit 70.8% salaris en 29.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.33% van de aandelen van het bedrijf, ter waarde € 9.81K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4 jaar en 2.5 jaar.

Belangrijke informatie

Eric Adams

Algemeen directeur

US$415.4k

Totale compensatie

Percentage CEO-salaris	70.8%
Dienstverband CEO	8.4yrs
Eigendom CEO	0.3%
Management gemiddelde ambtstermijn	4yrs
Gemiddelde ambtstermijn bestuur	2.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Eric Adams's beloning veranderd ten opzichte van InMed Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$7m
Jun 30 2024	US$415k	US$294k	-US$8m
Mar 31 2024	n/a	n/a	-US$6m
Dec 31 2023	n/a	n/a	-US$6m
Sep 30 2023	n/a	n/a	-US$7m
Jun 30 2023	US$368k	US$278k	-US$8m
Mar 31 2023	n/a	n/a	-US$15m
Dec 31 2022	n/a	n/a	-US$17m
Sep 30 2022	n/a	n/a	-US$19m
Jun 30 2022	US$468k	US$363k	-US$19m
Mar 31 2022	n/a	n/a	-US$14m
Dec 31 2021	n/a	n/a	-US$14m
Sep 30 2021	n/a	n/a	-US$12m
Jun 30 2021	US$735k	US$328k	-US$10m
Mar 31 2021	n/a	n/a	-US$9m
Dec 31 2020	n/a	n/a	-US$7m
Sep 30 2020	n/a	n/a	-US$8m
Jun 30 2020	US$424k	US$287k	-US$9m
Mar 31 2020	n/a	n/a	-US$10m
Dec 31 2019	n/a	n/a	-US$11m
Sep 30 2019	n/a	n/a	-US$10m
Jun 30 2019	US$1m	US$287k	-US$10m
Mar 31 2019	n/a	n/a	-US$9m
Dec 31 2018	n/a	n/a	-US$8m
Sep 30 2018	n/a	n/a	-US$7m
Jun 30 2018	US$2m	US$240k	-US$6m

Compensatie versus markt: De totale vergoeding ($USD 415.40K ) Eric } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 471.14K ).

Compensatie versus inkomsten: De vergoeding van Eric is gestegen terwijl het bedrijf verliesgevend is.

CEO

Eric Adams (60 yo)

8.4yrs

Tenure

US$415,400

Compensatie

Mr. Eric A. Adams, B.S. Chem., MIBS., has been the Chief Executive Officer and President at InMed Pharmaceuticals Inc. since June 16, 2016. Mr. Adams served as a Strategic Advisor of Augurex Life Sciences...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Eric Adams	President	8.4yrs	US$415.40k	0.33% € 9.8k
N. Jagpal	CFO & Corporate Secretary	less than a year	US$274.85k	0% € 0
Michael Woudenberg	Chief Operating Officer	2.3yrs	US$349.20k	0.00015% € 4.5
Alexandra Mancini	Senior Vice President of Clinical & Regulatory Affairs	8.1yrs	US$313.60k	0% € 0
Eric Hsu	Senior Vice President of Preclinical Research & Development	6.7yrs	US$322.50k	0.00045% € 13.4
Sazzad Hossain	Co-Founder	no data	US$142.43k	geen gegevens
Sarah Li	VP of Accounting & Controller	4.8yrs	geen gegevens	geen gegevens
Colin Clancy	Senior Director of Investor Relations	no data	geen gegevens	geen gegevens
Jerry Griffin	Vice President of Sales & Marketing	2.8yrs	geen gegevens	geen gegevens
Shane Johnson	Senior VP & GM of BayMedica	3.1yrs	geen gegevens	geen gegevens
Ado Muhammad	Senior Consultant of Medical Affairs	no data	geen gegevens	geen gegevens

4.0yrs

Gemiddelde duur

57.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van MWG wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Eric Adams	President	8.4yrs	US$415.40k	0.33% € 9.8k
Andrew Hull	Independent Chair of the Board	8.2yrs	US$77.50k	0.29% € 8.5k
Bryan Baldasare	Independent Director	2.5yrs	US$52.50k	0% € 0
Barry Greenberg	Member of the Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Janet Grove	Independent Director	2.8yrs	US$52.50k	0% € 0
Nicole Lemerond	Independent Director	2.3yrs	US$52.50k	0% € 0
David Morgan	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens

2.5yrs

Gemiddelde duur

58.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van MWG wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.5 jaar), wat duidt op een nieuw bestuur.

InMed Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

High number of new and inexperienced directors

InMed Pharmaceuticals Inc. Announces the Appointment of Dr. Barry Greenberg to Its Scientific Advisory Board

InMed Pharmaceuticals Inc., Annual General Meeting, Dec 18, 2024

InMed Pharmaceuticals Inc. Announces Chief Financial Officer Changes, Effective February 20, 2024

InMed Pharmaceuticals Inc., Annual General Meeting, Dec 19, 2023

InMed Pharmaceuticals Inc. Appoints Jonathan Tegge as Interim Chief Financial Officer

Recent updates

First quarter 2025 earnings released: US$2.71 loss per share (vs US$15.24 loss in 1Q 2024)

High number of new and inexperienced directors

InMed Pharmaceuticals Inc. Announces the Appointment of Dr. Barry Greenberg to Its Scientific Advisory Board

New major risk - Financial position

Full year 2024 earnings released: US$1.01 loss per share (vs US$3.25 loss in FY 2023)

InMed Pharmaceuticals Inc., Annual General Meeting, Dec 18, 2024

InMed Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $1.03019 million.

Third quarter 2024 earnings released: US$0.18 loss per share (vs US$0.60 loss in 3Q 2023)

InMed Pharmaceuticals Inc. Announces Additional Preclinical Data Demonstrating INM-901'S Positive Pharmacological Effects in the Potential Treatment of Alzheimer's Disease

Second quarter 2024 earnings released: US$0.18 loss per share (vs US$0.91 loss in 2Q 2023)

InMed Pharmaceuticals Inc. Announces Chief Financial Officer Changes, Effective February 20, 2024

Inmed Pharmaceuticals Inc. Announces the Launch of Inm-089

InMed Pharmaceuticals Inc. Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023

InMed Pharmaceuticals Inc. announced that it has received CAD 5.000002 million in funding

Inmed Pharmaceuticals Inc. Selects A Lead Alzheimer's Disease Drug Candidate, Named INM-901

InMed Pharmaceuticals Inc. announced that it expects to receive CAD 2.500001 million in funding

InMed Pharmaceuticals Inc. announced delayed annual 10-K filing

Full year 2023 earnings released: US$3.25 loss per share (vs US$33.17 loss in FY 2022)

InMed Pharmaceuticals Inc., Annual General Meeting, Dec 19, 2023

InMed Pharmaceuticals Inc. announced delayed 10-Q filing

InMed Pharmaceuticals Inc. Appoints Jonathan Tegge as Interim Chief Financial Officer

InMed Pharmaceuticals Inc. announced that it has received CAD 6.000011 million in funding

Inmed Pharmaceuticals Inc. Announces Promotion of Sarah Li to Controller and Principal Accounting Officer

Inmed Pharmaceuticals Inc. Provides Update on Management Changes

InMed Pharmaceuticals Advances Neurodegenerative Disease Program with Natural Sciences and Engineering Research Council of Canada Alliance Grant Funding

InMed Pharmaceuticals Inc., Annual General Meeting, Dec 15, 2022

InMed Pharmaceuticals Inc. to Report Fiscal Year 2022 Results on Sep 23, 2022

InMed Pharmaceuticals Inc. announced that it has received $6.000007 million in funding

InMed Pharmaceuticals Inc. announced that it expects to receive $6.000007 million in funding

Less than half of directors are independent

InMed Pharmaceuticals Inc. Appoints Nicole Lemerond to Its Board of Directors

InMed Pharmaceuticals Inc. Provides an Update on Its Phase 2 Clinical Trial

InMed Pharmaceuticals Inc. Announces Michael Woudenberg Has Been Appointed Chief Operating Officer

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharmaceuticals Inc. Receives Written Notice from the Listing Qualifications Department Staff of the Nasdaq Capital Market

InMed Pharmaceuticals Inc. Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions

InMed Pharmaceuticals Inc. announced that it has received $1.499999 million in funding

InMed Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $3.500002 million.

InMed Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $4.25 million.

Inmed Pharmaceuticals Inc. Announces Appointment of Bryan Baldasare to Its Board of Directors Effective May 13, 2022

InMed Pharmaceuticals Inc. Cannabidivarin, Expanding its Rare Cannabinoid Portfolio for the Health and Wellness Sector

InMed Pharmaceuticals Inc. Announces Board Changes

InMed Pharmaceuticals Inc. to Report Q2, 2022 Results on Feb 15, 2022

InMed Launches Cannabicitran (CBT), Expanding Its Rare Cannabinoid Portfolio for the Health and Wellness Sector

InMed Pharmaceuticals Inc. announced that it has received $12 million in funding

InMed Pharmaceuticals Inc. (NasdaqCM:INM) entered into a nonbinding letter of intent to acquire BayMedica Inc. for $4.7 million.

Inmed Pharmaceuticals Increases Cannabinoid Yield to 5 G/L with IntegraSyn in Advance of Commercial Scale Production

InMed Pharmaceuticals Inc. Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa

InMed Pharmaceuticals Achieves 2G/L Cannabinoid Yield with Integrasyn

InMed Pharmaceuticals Inc. announced that it has received $4.4625 million in funding

New 90-day high: €4.22

InMed Pharmaceuticals Inc. announced that it expects to receive $4.499998 million in funding

InMed Pharmaceuticals Inc. Announces Top-Line Results from Its 755-102-HV Phase 1 clinical trial

New 90-day low: €2.58

InMed Pharmaceuticals Inc. Licenses MiDROPS Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids

InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd